Funding Opportunity RFA-OD-20-020 from the NIH Guide for Grants and Contracts. The goal of this RFA is to solicit direct to Phase II SBIR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks 1) to advance novel biosensing technologies that are innovative, safe, and effective, and 2) to implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings. For skin monitoring, the device can include Electronic-nose (E-nose) technology or Gas Chromatography (GC). Thus, we are calling this program, the SCENT (Screening for COVID-19 by E-Nose Technology). Biosensing devices for the oral cavity can be technologies that have been thoroughly characterized as safe and effective in preclinical studies. Non-invasive, real-time, continuous or periodic measurements of VOCs and other biomarkers in breath, and emanating from oral tissues as signatures of onset, progression, and resolution of COVID-19 are desirable.

Funding Opportunity RFA-OD-20-019 from the NIH Guide for Grants and Contracts. NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Funding Opportunity RFA-OD-20-018 from the NIH Guide for Grants and Contracts. In response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS) for the 2019 Novel Coronavirus (COVID-19), the National Institutes of Health (NIH) has launched the Rapid Acceleration of Diagnostics (RADx) project. This emergency funding opportunity announcement (FOA) from NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH requires that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the companion Data Coordinating Center (DCC) funding opportunity announcement.

Funding Opportunity RFA-OD-20-017 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this initiative is to solicit applications for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from new and emerging viruses. Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19.

Funding Opportunity RFA-OD-20-016 from the NIH Guide for Grants and Contracts. NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.

Funding Opportunity RFA-OD-20-015 from the NIH Guide for Grants and Contracts. As one of the programs within the NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program (https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs#radx-rad), the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19. Wastewater testing has been shown to be orders of magnitude less expensive and faster than clinical screening, albeit serving as a complementary approach rather than substituting individual-level testing and screening. The purpose of this FOA is to solicit cooperative agreements both for field studies and for technology research and development projects capitalizing on partnerships with small business entities in the field of WBT, to address topics such as: investigation and demonstration of specific approaches aiming to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models to facilitate early detection of hotspots of virus spread. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Funding Opportunity RFA-OD-20-014 from the NIH Guide for Grants and Contracts. NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit proposals for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this RFA will support the early stage development of an innovative platform that integrates aptamer biosensing with touchscreen or other digital devices to achieve real-time detection and tracing of SARS-CoV-2. The project needs to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, immobilized sensor functionality, automatic signal transduction and detection by digital devices. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH expects that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the Data Coordinating Center (DCC) funding opportunity

Notice NOT-OD-20-152 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-159 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-149 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-810 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-156 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-094 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-074 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-20-003 from the NIH Guide for Grants and Contracts. The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Funding Opportunity PAR-20-270 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).

Funding Opportunity PAR-20-294 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

Notice NOT-GM-20-050 from the NIH Guide for Grants and Contracts

Notice NOT-LM-20-015 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-286 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for research centers to support integrated programs of high-impact, practice-based research with near-term potential to address NIMH suicide prevention priorities and help achieve the National Action Alliance for Suicide Prevention goals of reducing the rate of suicide in the US. The Centers are intended to support transdisciplinary teams of clinical and mental health services researchers, behavioral/social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) engaged in transdisciplinary programs of research that could not be achieved using standard research project grant mechanisms. Research Centers will support the rapid development, refinement, and testing of effective and scalable approaches for intervening at key intercepts in the chain of care: for identifying high-risk individuals, for promoting continuity across key care transitions (e.g., following identification in the emergency department or discharge from inpatient care), and for intervening (including prevention strategies and treatment for acute risk)